Skip to main content

Month: April 2025

Dime Community Bancshares, Inc. Reports First Quarter 2025 EPS of $0.45; Adjusted EPS of $0.57

Continued Growth in Core Deposits and Business Loans On a Year-over-Year Basis Net Interest Margin Expands by 16 basis points on a Linked Quarter Basis to 2.95% HAUPPAUGE, N.Y., April 22, 2025 (GLOBE NEWSWIRE) — Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), today reported net income available to common stockholders of $19.6 million for the quarter ended March 31, 2025, or $0.45 per diluted common share, compared to net loss available to common stockholders of $22.2 million, or $(0.54) per diluted common share, for the quarter ended December 31, 2024 and net income available to common stockholders of $15.9 million for the quarter ended March 31, 2024, or $0.41 per diluted common share. First quarter 2025 results included $7.2 million of pre-tax...

Continue reading

Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 2025

Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 2025 Siili Solutions Plc Stock exchange release 22 April 2025 at 14:10 EEST This is a correction to the stock exchange release published by Siili Solutions Plc on 22 April 2025 at 9:30 am by which the company published its business review for the period 1 January – 31 March 2025. In the key figures table there was “Total full-time employees and subcontractors (FTE) at the end of the period” instead of two separate key figures “Number of full-time employees (FTE) at the end of the period” and “Number of full-time subcontractors (FTE) at the end of the period”. The corrected release is stated below as a whole and the revised report is attached to this release. Q1 2025 for Siili: Siili continued AI strategy implementation and actions for profitability...

Continue reading

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

– Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 – WAYNE, Pa, April 22, 2025 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1a/1b clinical trial of ATI-052, a potential best-in-class bispecific anti-TSLP/IL-4R monoclonal antibody. “Therapeutic innovation is at the core of the important work we do at Aclaris, and bispecific antibodies represent a groundbreaking innovation in immunotherapy that we believe will evolve the therapeutic armamentarium in a variety of settings,” said Dr. Hugh Davis, Aclaris’ President...

Continue reading

Northrop Grumman Releases First Quarter 2025 Financial Results

FALLS CHURCH, Va., April 22, 2025 (GLOBE NEWSWIRE) — Northrop Grumman Corporation (NYSE: NOC) has released its first quarter 2025 financial results. A copy of the earnings release has been furnished in the company’s Form 8-K filing and is also available on the company’s investor relations website at http://investor.northropgrumman.com. As previously announced, Northrop Grumman will webcast its earnings conference call at 9:30 a.m. Eastern time today. A live audio broadcast of the conference call will be available on http://investor.northropgrumman.com. Northrop Grumman is a leading global aerospace and defense technology company. Our pioneering solutions equip our customers with the capabilities they need to connect and protect the world, and push the boundaries of human exploration across the universe. Driven by a shared...

Continue reading

Li Auto Inc. to Hold Annual General Meeting on May 30, 2025

BEIJING, China, April 22, 2025 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it will hold an annual general meeting of the Company’s shareholders (the “AGM”) at 10:00 a.m. Beijing time on May 30, 2025 at 9/F, Office Tower C1, Oriental Plaza, 1 East Chang An Avenue, Beijing, China for the purposes of considering and, if thought fit, passing with or without amendments each of the proposed resolutions as set forth in the notice of the AGM (the “AGM Notice”). The AGM Notice, a circular in relation to the AGM, and the form of proxy for the AGM are available on the Company’s website at https://ir.lixiang.com. The board of directors of the Company fully supports the proposed resolutions and recommends that shareholders and holders...

Continue reading

Devon Energy Unveils Value Enhancing Business Optimization Plan

HIGHLIGHTSTargeting $1 billion in annual pre-tax free cash flow improvements Business optimization plan underway to improve margins and capital efficiency Plan includes improvements to base production performance, midstream commercial terms and corporate costs Expected to be completed by the end of 2026, with 30 percent achieved by year-end 2025OKLAHOMA CITY, April 22, 2025 (GLOBE NEWSWIRE) — Devon Energy Corp. (NYSE: DVN) today announced its business optimization plan to improve margins and capital efficiency, growing free cash flow generation and driving significant shareholder value. “I’m excited to announce the details of our business optimization plan, set to enhance margins and deliver $1 billion in annual pre-tax free cash flow improvements by year end 2026,” said Clay Gaspar, president and CEO. “This milestone reflects...

Continue reading

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, April 22, 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research Ethics Board has granted approval for Toronto General Hospital to participate in the Company’s ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With this ethics approval in place and all training and preparations complete, the clinical team at Toronto General Hospital (TGH) is now cleared to begin patient recruitment. TGH will be the seventh site to be activated globally and the second site to recruit patients in Canada. Quote from Mr. Richard Muruve, CEO Arch Biopartners: “​We are pleased to receive ethics approval from the UHN Research Ethics...

Continue reading

Verizon delivered strong financial growth with industry-leading wireless service revenue in 1Q 2025

Customer segmentation strategy is a key driver of successful financial performance Verizon remains confident in full-year 2025 guidance Key 1Q 2025 HighlightsIndustry-leading total wireless service revenue1 of $20.8 billion Best wireless retail core prepaid2 net additions since the TracFone acquisition Continued to take broadband market share with strong demand for Fios and fixed wireless access Verizon exits first quarter with momentum in both mobility and broadbandNEW YORK, April 22, 2025 (GLOBE NEWSWIRE) — Verizon Communications Inc. (NYSE, Nasdaq: VZ) today reported strong financial performance for the first-quarter of 2025, fueled by innovative and segmented product offerings that meet the ever-changing needs of consumers and businesses across market sectors. The company’s strategically designed portfolio of diversified...

Continue reading

Goodfood Reports Second Quarter of 2025 Results with Net Sales of $31 million, Gross Profit of $13 million and Adjusted EBITDA¹ of $1 million

Net sales were $31 million in the second quarter of 2025, with gross margin2 reaching 42.6% for a gross profit of $13 million Net loss of $2 million, adjusted EBITDA margin1 of 4.5% and adjusted EBITDA1 of $1 million for the quarter Cash flows used in operating activities of $1 million and adjusted free cash flow1 was negative $1 million for the second quarter of 2025 Cash balance and marketable securities at $19 million, with balance sheet further de-risked with repayment of 2025 Debentures on March 31, 2025 Attained B Corp certification, joining global community of forward-thinking companies using business as a force for good Genuine Tea, Goodfood’s first acquisition, performing well and benefitting from “Buy in Canada” movement, as we look to further build pipeline of deals and complete more acquisitions to expand our platformMONTREAL,...

Continue reading

Enerflex Ltd. Confirms Search for New Independent Director and Announces Timing of First Quarter Release

CALGARY, Alberta, April 22, 2025 (GLOBE NEWSWIRE) — The Board of Directors (the “Board”) of Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) today confirmed that, consistent with good corporate governance, it intends to initiate a search this year for a qualified independent director. The Board also announced that it is committed to achieve at least 30% gender diversity on the Board on or before the Company’s 2026 annual meeting. Q1 Earnings Release Enerflex plans to release its financial results and operating highlights for the three months ended March 31, 2025, prior to market open on Thursday, May 8, 2025. Results will be communicated by news release and will be available on the Company’s website at www.enerflex.com and under the electronic profile of the Company on SEDAR+ and EDGAR at www.sedarplus.ca...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.